Results 161 to 170 of about 1,320,527 (284)

Effects of raclopride, dopamine receptor antagonist, in rat model of nicotine dependence

, 2000
Effects of raclopride, a dopamine receptor antagonist, in a rat model of nicotine ...
Tessari M, Valerio E, CALDERAN, Laura, Andreoli M, CHIAMULERA, Cristiano   +4 more
core   +1 more source

In Silico Decoding of Nonsteroidal Mineralocorticoid Receptor Antagonist Binding: Implications for Drug Design. [PDF]

J Chem Inf Model
Pérez-Gordillo F, Carpio LE, Alvarez de la Rosa D, Martín-Martínez M.   +3 more
europepmc   +1 more source

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, EarlyView.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service

Internal Medicine Journal, EarlyView.
Abstract Aims To evaluate the sustained impact of the Endocrine Hypertension Service on primary aldosteronism (PA) diagnosis and management over a subsequent 3‐year period. Background PA is a prevalent yet underdiagnosed cause of secondary hypertension, associated with increased cardiovascular, renal and metabolic risk. Limited awareness, resources and
Minn W. Chow, Chrislyn Ng, Jimmy Shen, Peter J. Fuller, Jun Yang, Renata Libianto   +5 more
wiley   +1 more source

Discrepancies between forest plots and reported results in mineralocorticoid receptor antagonist meta-analysis of glycaemic outcomes. [PDF]

Br J Clin Pharmacol
Saha L.
europepmc   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy. [PDF]

Clin Cardiol
Imamura T.
europepmc   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

Journal of Diabetes Investigation, EarlyView.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Hiroaki Satoh, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +8 more
wiley   +1 more source

Trends in Steroidal Mineralocorticoid Receptor Antagonist Prescriptions by Nephrologists after Approval of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone for CKD. [PDF]

J Am Soc Nephrol
Edmonston D, Catanese B, Sparks M.
europepmc   +1 more source

Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR. [PDF]

J Clin Med, 2023
Imamura T, Narang N, Onoda H, Tanaka S, Ushijima R, Sobajima M, Fukuda N, Ueno H, Kinugawa K.   +8 more
europepmc   +1 more source